Compare RSSS & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSSS | GANX |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.6M | 76.4M |
| IPO Year | 2008 | 2021 |
| Metric | RSSS | GANX |
|---|---|---|
| Price | $2.31 | $1.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.00 | ★ $7.50 |
| AVG Volume (30 Days) | 51.0K | ★ 709.9K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.77 | 31.46 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $28,793,922.00 | $55,180.00 |
| Revenue This Year | $1.81 | N/A |
| Revenue Next Year | $5.73 | N/A |
| P/E Ratio | $33.29 | ★ N/A |
| Revenue Growth | ★ 2.77 | N/A |
| 52 Week Low | $2.00 | $1.41 |
| 52 Week High | $4.12 | $4.34 |
| Indicator | RSSS | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 50.92 | 50.05 |
| Support Level | $2.17 | $1.66 |
| Resistance Level | $2.37 | $2.15 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 53.85 | 26.79 |
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.